The FDA has recently sent a warning letter to one of the most prominent highly quoted dermatologist and clinical researcher in the nation, citing the doctor for expressing irresponsible and premature enthusiasm in the media for an injectable antiwrinkle drug that the FDA has not yet approved. Her comments, say the FDA, violated restrictions on drug promotions.
Under the Obama administration, the FDA has stepped up scrutiny of drug advertising particularly as it relates to symbiotic relationships some physicians have with pharmaceutical companies. This has clear implications for lawyers who practice pharmaceutical personal injury law. Now there is support from the government in those cases where patient injury results from drugs that have either not been properly tested or have not yet passed FDA scrutiny.
See the full article: Inadvertently deleted. If interested, go to January 31, 2010 New York Times Health Archive to view.
